NEW YORK (GenomeWeb News) — Diagnostics technologies developer Avacta Group and the University of Liverpool will collaborate to develop integrated microarray and mass spectrometry tools for use in detecting biomarkers and discovering new drug targets.

Wetherby, UK-based Avacta said today the partners will combine the firm's engineered affinity reagent microarrays, which it calls Affimer microarrays, and reagents with mass spectrometry tools developed by University of Liverpool Professor Rob Beynon.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.